Emerging Pharmaceutical Organization Awards $1.7 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Informat
15 June 2004 - 12:02AM
PR Newswire (US)
Emerging Pharmaceutical Organization Awards $1.7 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Thorough Phase I ECG Study to be Conducted
for Cardio-Renal Product PHILADELPHIA, June 14
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has received an agreement for about $1.7
million in cardiac safety monitoring and services from an emerging
pharmaceutical organization for one of its drug candidates in
clinical development. The agreement covers an extensive Phase I
study for which eRT is providing comprehensive support including
the provision, training and ongoing assistance required for
effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT(R) workflow-enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The study is targeted for
completion over a 90-day period. "With less than one month from
award to trial start, eRT is pleased to be in a position to meet
the demanding timeframes for this significant Thorough Phase I ECG
Study, which is critical to the clinical development program for
this compound," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT. "eRT's
scientific consulting helped the drug developer implement an
optimal plan for ECG collection and analysis for this novel therapy
in the Cardio-Renal Division of the FDA, and our company's
unmatched capacity and throughput will help to ensure on-schedule
study conduct." Based in Philadelphia, PA, eResearchTechnology,
Inc. (http://www.ert.com/) is a provider of technology and services
to the pharmaceutical, biotechnology and medical device industries
on a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology, Inc. Web
site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles